InfuSystem reports record 2025 revenue $143.4M, adj. EBITDA $31.5M, net leverage 0.52x

InfuSystem Holdings, Inc

2025 net revenue $143.4M, up 6.3% YoY from $134.9M; seven consecutive years of record revenue.
2025 adjusted EBITDA of $31.5M (21.9% margin) vs $25.3M (18.8%) in 2024; cash flow from operations $24.4M.
Patient Services revenue $86.5M (60% of total), Device Solutions $56.9M (40%); gross margin 56.0%.
Share repurchase program: $11.0M bought back through Dec 31, 2025; $20M authorization expires June 2026.
Net leverage 0.52x, debt/equity 0.75x, total available liquidity $58.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.